Photo taken from Benedetta Pellegrino/X
Jul 9, 2024, 22:15
Benedetta Pellegrino: Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1
Benedetta Pellegrino, Resident in Medical Oncology at the University Hospital of Parma, shared on X:
“Discover our latest study on the validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1 in breast and ovarian cancer! ”
Read further.
Source: Benedetta Pellegrino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 31, 2024, 17:57
Dec 31, 2024, 11:53
Dec 31, 2024, 11:16
Dec 31, 2024, 11:03
Dec 31, 2024, 10:54
Dec 31, 2024, 10:28
Dec 31, 2024, 10:13
Dec 31, 2024, 09:57